

ASTRAZENECA PLC
Form 6-K
March 19, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of March 2015
Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

NOTICE OF ANNUAL GENERAL MEETING

Edgar Filing: ASTRAZENECA PLC - Form 6-K

AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2015 and Shareholders' Circular; a covering letter from the Chairman; and 'AstraZeneca 2014 In Brief'.

Copies of the documents have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm. The documents are also available on the Company's website at www.astrazeneca.com/agm.

The Company's Annual Report and Form 20-F Information 2014 was published on 10 March 2015.

The above documents are being despatched to shareholders today.

The meeting place for the Annual General Meeting (AGM) will be the Lancaster London Hotel, Lancaster Terrace, London, W2 2TY and the AGM will commence at 2.30 pm (BST) on 24 April 2015.

A C N Kemp
Company Secretary
19 March 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 19 March 2015

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary